[Skip to Content]
[Skip to Content Landing]
July 31, 1967

Hypoplastic Anemia and Carbamazepine Therapy

JAMA. 1967;201(5):332-333. doi:10.1001/jama.1967.03130050066033

To the Editor:—  I read with interest "Use of Carbamazepine in Epilepsy" by Livingston et al (200: 204, 1967) and noted their reports of further cases of hematopoietic disturbance following the administration of this drug.The authors refer to a nonfatal case of hypoplastic anemia attributed to carbamazepine by me and my colleagues.1 This case was subsequently described in more detail,2 and in the discussion of the then documented cases attention was drawn to the long duration of treatment and large total dose administered. However, I have never believed that these factors were solely responsible, as many sufferers from trigeminal neuralgia have been treated in the United Kingdom with similar quantities of the drug without developing bone marrow failure. Therefore, individual susceptibility or some other factor must be involved. I know of no published studies on the mechanism of the hematopoietic disturbance.As these blood dyscrasias have been